Shots: The EC’s approval is based on P-III ARAMIS study assessing Nubeqa (600mg, bid) + ADT vs PBO + ADT 1,509 patients in a ratio (2:1) with nmCRPC The P-III […]readmore
Tags : Non-Metastatic Castration-Resistant Prostate Cancer
Shots: The P-III PROSPER study involves assessing of Xtandi (160mg, QD) + ADT vs PBO + ADT in 1400 patients with nmCRPC across the US, EU, SA, Canada, and the […]readmore
Shots: The P-III ARAMIS study involves assessing of Nubeqa (600mg, bid) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC who were receiving a […]readmore
Shots: The approval is based on P-III ARAMIS study assessing Nubeqa (600mg, qd) + ADT vs PBO + ADT in 1,509 patients in a ratio (2:1) with nmCRPC The P-III […]readmore
Shots: The approval is based on P-III ARAMIS study results assessing Nubeqa (600mg, bid) + ADT vs PBO + ADT in 1,509 in patients in a ratio (2:1) with nmCRPC. […]readmore
Shots: The P-III ARAMIS trial involves assessing of Darolutamide (600 mg, bid) + androgen deprivation therapy (ADT) vs PBO + ADT in 1509 patients in the ratio (2:1) with nmCRPC […]readmore
Janssen’s Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate
Shots: The approval is based on P-III SPARTAN study results assessing Erleada (240 mg,qd) vs PBO in 1,207 patients with NM-CRPC in ratio (2:1) in patients with (NM-CRPC) P-III SPARTAN […]readmore